Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed May 4, 2023 · 10-Q · 34 days after period end · 0000899923-23-000035
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $181.20M | $164.90M | $173.10M | $164.00M |
| Net Income | -$54.70M | -$20.50M | -$39.50M | -$115.20M |
| EPS Diluted | -$0.67 | -$0.26 | -$0.52 | -$1.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end
